SG Americas Securities LLC Has $116,000 Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

SG Americas Securities LLC increased its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 60.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,742 shares of the company’s stock after buying an additional 6,323 shares during the period. SG Americas Securities LLC’s holdings in Monte Rosa Therapeutics were worth $116,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in Monte Rosa Therapeutics by 10,665.5% during the 4th quarter. GAMMA Investing LLC now owns 5,921 shares of the company’s stock worth $41,000 after purchasing an additional 5,866 shares during the last quarter. Intech Investment Management LLC bought a new position in Monte Rosa Therapeutics during the 3rd quarter worth approximately $77,000. JPMorgan Chase & Co. raised its holdings in Monte Rosa Therapeutics by 38.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 18,543 shares of the company’s stock worth $98,000 after purchasing an additional 5,125 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Monte Rosa Therapeutics by 54.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 24,100 shares of the company’s stock worth $128,000 after purchasing an additional 8,500 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in Monte Rosa Therapeutics during the 3rd quarter worth approximately $132,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GLUE has been the subject of several analyst reports. Wells Fargo & Company lowered shares of Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $14.00 to $11.00 in a report on Thursday, December 19th. Wedbush reiterated an “outperform” rating and issued a $15.00 price objective on shares of Monte Rosa Therapeutics in a research note on Thursday, November 7th.

Monte Rosa Therapeutics Stock Down 5.3 %

NASDAQ:GLUE opened at $6.11 on Wednesday. The company has a fifty day moving average of $6.85 and a 200-day moving average of $6.56. The firm has a market capitalization of $375.40 million, a P/E ratio of -3.34 and a beta of 1.46. Monte Rosa Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $12.40.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.